spacer
home > pmps > summer 2017 > seasonal substances
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Seasonal Substances

The UK is experiencing a good start to the summer this year, with some areas having faced the hottest day since 1976. However, this period also brings discomfort to the country’s estimated 18 million hay fever sufferers. Relief is available in the form of remedies such as antihistamines and, inevitably, sales of these soar during the summer months, adding a seasonal dimension to managing the manufacture and distribution of these products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Robert Harris is Chief Technical Officer at Juniper Pharma Services and PMPS Industry Advisor.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Perfect Gx Elite vials presented by Gerresheimer at CPhI Worldwide

Düsseldorf/Frankfurt, October 24, 2017. The Gx Elite vials have set new standards for type 1 borosilicate glass vials. They are the result of comprehensive optimization measures in the conversion process, which have focused on designing out the risk to create product flaws during production including the removal of all glass-to-glass contact beginning with the tubing material all the way through final packaging. The chemical composition of the borosilicate glass is still the same. Gerresheimer will be showcasing Gx Elite vials at booth D02 in Hall 4.2 at CPhI Worldwide in Frankfurt (Germany) from October 24 to 26, 2017.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement